Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1949 1
1951 2
1952 1
1953 1
1964 1
1967 1
1968 2
1971 1
1972 8
1973 3
1974 2
1975 4
1976 2
1977 5
1978 2
1979 6
1980 6
1981 6
1982 5
1983 4
1984 1
1985 1
1986 1
1989 2
1991 1
1994 3
1995 1
1996 1
1997 2
1999 2
2000 1
2001 3
2002 3
2004 3
2005 7
2006 6
2007 6
2008 5
2009 10
2010 11
2011 6
2012 9
2013 12
2014 21
2015 19
2016 23
2017 25
2018 21
2019 14
2020 19
2021 15
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

302 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: dent r. N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549. N Engl J Med. 2020. PMID: 32101663 Clinical Trial.
What is the role of immunotherapy in breast cancer?
Tan TJ, Chan JJ, Kamis S, Dent RA. Tan TJ, et al. Among authors: dent ra. Chin Clin Oncol. 2018 Apr;7(2):13. doi: 10.21037/cco.2018.04.01. Chin Clin Oncol. 2018. PMID: 29764158 Free article. Review.
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Schmid P, Salgado R, Park YH, Muñoz-Couselo E, Kim SB, Sohn J, Im SA, Foukakis T, Kuemmel S, Dent R, Yin L, Wang A, Tryfonidis K, Karantza V, Cortés J, Loi S. Schmid P, et al. Among authors: dent r. Ann Oncol. 2020 May;31(5):569-581. doi: 10.1016/j.annonc.2020.01.072. Epub 2020 Feb 14. Ann Oncol. 2020. PMID: 32278621 Free article. Clinical Trial.
IL-1 induces mitochondrial translocation of IRAK2 to suppress oxidative metabolism in adipocytes.
Zhou H, Wang H, Yu M, Schugar RC, Qian W, Tang F, Liu W, Yang H, McDowell RE, Zhao J, Gao J, Dongre A, Carman JA, Yin M, Drazba JA, Dent R, Hine C, Chen YR, Smith JD, Fox PL, Brown JM, Li X. Zhou H, et al. Among authors: dent r. Nat Immunol. 2020 Oct;21(10):1219-1231. doi: 10.1038/s41590-020-0750-1. Epub 2020 Aug 10. Nat Immunol. 2020. PMID: 32778760 Free PMC article.
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Yeong J, Tan T, Chow ZL, Cheng Q, Lee B, Seet A, Lim JX, Lim JCT, Ong CCH, Thike AA, Saraf S, Tan BYC, Poh YC, Yee S, Liu J, Lim E, Iqbal J, Dent R, Tan PH. Yeong J, et al. Among authors: dent r. J Clin Pathol. 2020 Sep;73(9):557-562. doi: 10.1136/jclinpath-2019-206252. Epub 2020 Jan 22. J Clin Pathol. 2020. PMID: 31969377
Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, Mok ZY, Koh KX, Toh HC, Koo WH, Loh M, Ng RCH, Choo SP, Soong RCT. Yap YS, et al. Among authors: dent ra. JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269. JAMA Oncol. 2017. PMID: 28715540 Free PMC article. Clinical Trial.
302 results